Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

[18F]MNI-798 for Imaging Tau in Alzheimer's Disease

Start: November 2015
End: June 2019
Enrollment: 60

What Is This Study About?

This study will evaluate changes in the protein tau in the brain of people at different stages of Alzheimer's disease and in healthy volunteers. Tau deposition, which is seen in the brain of people with  Alzheimer's or some other dementias, will be measured in a series of four brain scans using the imaging agent [18F]MNI-798.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 80 Years

Must have:

  • Very early, mild, or moderate Alzheimer's-type dementia
  • For cognitively healthy participants: Brain MRI consistent with no significant ischemic changes or other pathology that may interfere with PET imaging analysis

Participants with Alzheimer's

  • Screening PET scan showing amyloid binding
  • Study partner who is willing to accompany participant to study visits
  • If taking medications for Alzheimer's symptoms, must be on stable dose for at least 30 days prior to screening visit

Must NOT have:

  • Unwilling or unable to provide informed consent
  • Current or prior history of any drug or alcohol abuse
  • Pregnant or lactating women
  • Any significant psychiatric, neurological, or unstable medical disorder expected to interfere with the study
  • Unable to undergo MRI scan, PET scan, or lumbar puncture
  • Current, past, or anticipated exposure to radiation, including radiation exposure in the workplace or participation in nuclear medicine procedures

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Who Is the General Study Contact?

For more information about this trial or the study sites, please call 1-888-662-6728 or email global.rochegenentechtrials@roche.com.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Molecular NeuroImaging

Collaborator Sponsor

  • Genentech, Inc.

Source: ClinicalTrials.gov ID: NCT02640092

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health